New York, NY (October 20, 2020) – Ezra, the NY-based startup transforming early cancer screening using MRI, announced today that it has received FDA 510(k) clearance for its Artificial Intelligence designed to assist radiologists in analyzing and segmenting prostate MRI.
Use of the innovative AI technology can help reduce the time and cost of MRI-based prostate cancer screening. It is the first Prostate AI to ever be cleared by the FDA.
As a result of ezra implementing this new AI technology in its cancer screening service, ezra is decreasing the price of the Ezra scan by 15%, to $575.
The Ezra AI achieves three important goals:
To integrate the ezra Prostate AI into radiology workflows, ezra has also obtained FDA clearance for Plexo, a cloud-based PACS (Picture Archiving and Communications System) that works directly in the browser. This enables radiologists to use the ezra platform without the need to install any software.
“Ezra is at the forefront of MRI-based cancer screening, and the company’s 510k FDA clearance for its Prostate AI is further validation of its innovation capabilities,” said Lawrence Tanenbaum, M.D., FACR, Vice president and CTO, Director of MRI, CT and Advanced Imaging at RadNet.
Ezra launched its MRI-based prostate cancer screening service in January 2019, and rolled out its full-body MRI scan in May 2019.
Ezra partners with existing outpatient imaging facilities, and all ezra scans are analyzed by board-certified radiologists. The company’s cancer screening programs are live in New York City, San Francisco, and Los Angeles through its partnership with RadNet, Inc., the nation’s leader in outpatient imaging. In 2019, ezra helped 4% of its members – all of whom were asymptomatic – detect cancer.
Ezra is a New York-based healthcare technology company utilizing medical imaging and Artificial Intelligence to provide individuals with full-body cancer screening that is fast, accurate, and affordable.
By advocating for early cancer detection as part of annual health screenings, ezra is on a mission to create a new standard of preventative care, providing people with the necessary knowledge to make decisions about their health. The company’s cancer screening services are available in New York, San Francisco, and Los Angeles.